The COVID-19 Textbook

263

CHAPTER 8 • Antibodies in COVID-19

156. Tang J, Zeng C, Cox TM, et al . Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol . 2022;7:eadd4853. 157. Li M, Wang Y, Sun Y, Cui H, Zhu SJ, Qiu HJ . Mucosal vaccines: strategies and challenges. Immunol Lett . 2020;217:116-125. 158. Azzi L, Dalla Gasperina D, Veronesi G, et al . Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine . 2022;75:103788. 159. Wang X, Zhou P, Wu M, et al . Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection. NPJ Vaccines . 2020;5:57. 160. Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Protective immunity after natural infection with severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2)—Kentucky, USA, 2020. Int J Infect Dis . 2022;114:21-28. 161. Lee ARYB, Wong SY, Chai LYA, et al . Efficacy of Covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ . 2022;376:e068632. doi:10.1136/bmj-2021-068632 162. Choi A, Koch M, Wu K, et al . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med . 2021;27:2025-2031. 163. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al . Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell . 2020;183:996-1012.e19. 164. Natarajan K, Prasad N, Dascomb K, et al . Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults—VISION network, 10 states, December 2021-March 2022. MMWR Morb Mortal Wkly Rep . 2022;71:495-502. 165. Marson P, Cozza A, de Silvestro G. The true historical origin of convalescent plasma therapy. Transfus Apher Sci . 2020;59:102847. 166. Klassen SA, Senefeld J, Johnson PW, et al . The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. medRxiv . 2021;2020.07.29.20162917. doi:10.1101/2020.07.29.20162917 167. Klassen SA, Senefeld JW, Johnson PW, et al . The Effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc . 2021;96:1262-1275. 168. Joyner MJ, Carter RE, Fairweather D, Wright RS. Convalescent plasma and COVID-19: Time for a second-second look? Transfus Med . 2023;33:16-20. doi:10.1111/tme.12915 169. Kloypan C, Saesong M, Sangsuemoon J, Chantharit P, Mongkhon P. CONVALESCENT plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence. Eur J Clin Invest . 2021;51:e13663. 170. Sullivan DJ, Gebo KA, Shoham S, et al . Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med . 2022;386:1700-1711. 171. Tworek A, Jaroń K, Uszyńska-Kałuża B, et al . Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients—propensity-score matched case-control study. Int J Infect Dis . 2021;105:209-215. 172. Bégin P, Callum J, Jamula E, et al . Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med . 2021;27:2012-2024. 173. Bar KJ, Shaw PA, Choi GH, et al . A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest . 2021;131:e155114. 174. Thompson MA, Henderson JP, Shah PK, et al . Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol . 2021;7:1167-1175. 175. Herman JD, Wang C, Burke JS, et al . Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. Cell Rep Med . 2022;3:100811. 176. Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell . 2021;184:3086-3108. 177. Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol . 2023;23:381-396. doi:10.1038/s41577-022-00813-1 178. Wrapp D, Wang N, Corbett KS, et al . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science . 2020;367:1260-1263. 179. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res . 2019;105:93-116. 180. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D . Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell . 2020;181:281-292.e6. 181. Barnes CO, Jette CA, Abernathy ME, et al . SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature . 2020;588:682-687. 182. Cerutti G, Guo Y, Wang P, et al . Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Rep . 2021;37:109928. 183. Chi X, Yan R, Zhang J, et al . A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science . 2020;369:650-655. 184. Suryadevara N, Shrihari S, Gilchuk P, et al . Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell . 2021;184:2316-2331.e15. 185. Pinto D, Sauer MM, Czudnochowski N, et al . Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science . 2021;373:1109-1116. 186. Dacon C, Tucker C, Peng L, et al . Broadly neutralizing antibodies target the coronavirus fusion peptide. Science . 2022;377:728-735. 187. Starr TN, Greaney AJ, Addetia A, et al . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science . 2021;371:850-854. 188. Wang P, Nair MS, Liu L, et al . Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature . 2021;593:130-135. 189. Liu L, Iketani S, Guo Y, et al . Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature . 2022;602:676-681. 190. Gilchuk P, Murin CD, Milligan JC, et al . Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization. Immunity . 2020;52:388-403.e12. 191. Saphire EO, Aman MJ. Feverish quest for Ebola immunotherapy: straight or cocktail? Trends Microbiol . 2016;24:684-686. 192. Starr TN, Greaney AJ, Hannon WW, et al . Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science . 2022;377:420-424. 193. Yamin R, Jones AT, Hoffmann HH, et al . Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature . 2021;599:465-470. 194. Titong A, Gallolu Kankanamalage S, Dong J, et al . First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants. Sci Rep . 2022;12:4163. 195. de Gasparo R, Pedotti M, Simonelli L, et al . Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature . 2021;593:424-428. 196. Misasi J, Wei RR, Wang L, et al . A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization. bioRxiv . 2022;2022.07.29.502029. doi:10.1101/2022.07.29.502029 197. Yuan M, Chen X, Zhu Y, et al . A bispecific antibody targeting RBD and S2 potently neutralizes SARS-CoV-2 omicron and other variants of con cern. J Virol . 2022;96:e0077522. 198. Zhang J, Zhang H, Sun L. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? MAbs . 2022;14:2031483. 199. Ku Z, Xie X, Hinton PR, et al . Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature . 2021;595:718-723. 200. Caskey M. Delivery of anti-HIV bNAbs by viral vectors. Lancet HIV . 2019;6:e207-e208. 201. Moffett HF, Harms CK, Fitzpatrick KS, Tooley MR, Boonyaratanakornkit J, Taylor JJ . B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol . 2019;4:eaax0644. 202. Li JQ, Zhang ZR, Zhang HQ, et al . Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. Signal Transduct Target Ther . 2021;6:369. 203. August A, Attarwala HZ, Himansu S, et al . A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med . 2021;27:2224-2233.

Copyright © 2023 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.